跨国药企迎战略重构|记“医”2025

21世纪经济报道
Dec 29, 2025

头部跨国药企在2025年经历了天差地别的命运分化。  从财报数据中就可看出其中的端倪。根据财报显示,诺和诺德公布的2025年第三季度业绩报告显示,第三季度总营收749.76亿丹麦克朗(约112.76亿美元),同比增长11%;2025年前三季度总营收达2299.20亿丹麦克朗(约345.8亿美元),同比增长15%。司美格鲁肽系列产品持续领跑业绩,三大品牌销售额表现亮眼:Ozempic(降糖版):...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10